Literature DB >> 22198256

Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.

J L Hopper1, M A Jenkins, J G Dowty, G S Dite, C Apicella, L Keogh, A K Win, J P Young, D Buchanan, M D Walsh, C Rosty, L Baglietto, G Severi, K A Phillips, E M Wong, A Dobrovic, P Waring, I Winship, S J Ramus, G G Giles, M C Southey.   

Abstract

Genes have been identified for which germline mutations are associated with high lifetime risks of breast, colorectal and other cancers. Identification of mutation carriers through genetic testing is important as it could help lower cancer incidence and mortality. The translation of genetic information into better health outcomes is expensive because of the costs of genetic counselling as well as laboratory testing. Approaches to triage for mutation screening of known genes which rely on cancer family history are not necessarily sensitive and specific or the most cost-effective. Recent population-based research has shown that the cancers and precancerous lesions arising in mutation carriers have specific molecular and morphological characteristics. People with colorectal cancer, especially those diagnosed at a young age, whose tumours exhibit microsatellite instability and some specific pathology and immunohistochemically-defined features are more likely to carry a germline mutation in one of four mismatch repair genes. Some morphological and immunohistochemically-defined features are associated with breast cancers arising in women who carry BRCA1 or BRCA2 germline mutations, especially if at a young age. Screening paradigms based on molecular and morphological features that predict mutation status, especially if focused on early-onset disease, have the potential to identify mutation carriers with greater sensitivity and specificity, and in a more cost-effective way, than those based on family history alone. Genetic testing results could help inform treatment if those affected are tested soon after diagnosis using pathology-led selection strategies to identify cases most likely to carry germline mutations. We propose how this new approach could be undertaken by having genetic testing and counselling prioritised to those with the greatest probability of carrying a germline mutation in these known cancer predisposition genes.

Entities:  

Mesh:

Year:  2012        PMID: 22198256     DOI: 10.1097/PAT.0b013e32834e8e5b

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

1.  Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.

Authors:  Aung Ko Win; Daniel D Buchanan; Christophe Rosty; Robert J MacInnis; James G Dowty; Gillian S Dite; Graham G Giles; Melissa C Southey; Joanne P Young; Mark Clendenning; Michael D Walsh; Rhiannon J Walters; Alex Boussioutas; Thomas C Smyrk; Stephen N Thibodeau; John A Baron; John D Potter; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Steven Gallinger; Noralane M Lindor; John L Hopper; Dennis J Ahnen; Mark A Jenkins
Journal:  Gut       Date:  2014-03-10       Impact factor: 23.059

2.  Cancer family history triage: a key step in the decision to offer screening and genetic testing.

Authors:  Paul Brennan; Oonagh Claber; Tracey Brennan
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

3.  Tumour morphology predicts PALB2 germline mutation status.

Authors:  Z L Teo; E Provenzano; G S Dite; D J Park; C Apicella; S D Sawyer; P A James; G Mitchell; A H Trainer; G J Lindeman; K Shackleton; L Cicciarelli; S S Buys; I L Andrulis; A M Mulligan; G Glendon; E M John; M B Terry; M Daly; F A Odefrey; T Nguyen-Dumont; G G Giles; J G Dowty; I Winship; D E Goldgar; J L Hopper; M C Southey
Journal:  Br J Cancer       Date:  2013-06-20       Impact factor: 7.640

4.  Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.

Authors:  Sarah L Daniels; George J Burghel; Philip Chambers; Shadi Al-Baba; Daniel D Connley; Ian W Brock; Helen E Cramp; Olena Dotsenko; Octavia Wilks; Lynda Wyld; Simon S Cross; Angela Cox
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.